ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 127 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,739 | -98.7% | 3,399 | -98.6% | 0.00% | – |
Q1 2024 | $298,965 | +31.0% | 241,101 | +10.9% | 0.00% | – |
Q4 2023 | $228,222 | -56.5% | 217,354 | +183.7% | 0.00% | -100.0% |
Q3 2023 | $524,778 | +65.7% | 76,610 | +150.8% | 0.00% | – |
Q2 2023 | $316,762 | +6.0% | 30,546 | -17.3% | 0.00% | – |
Q1 2023 | $298,853 | +111.0% | 36,941 | +310.7% | 0.00% | – |
Q4 2022 | $141,656 | -100.0% | 8,994 | -57.3% | 0.00% | -100.0% |
Q3 2022 | $331,705,000 | +77.9% | 21,074 | +57.8% | 0.00% | – |
Q2 2022 | $186,464,000 | +144.4% | 13,357 | +201.8% | 0.00% | – |
Q1 2022 | $76,304,000 | -51.6% | 4,426 | -59.2% | 0.00% | – |
Q4 2021 | $157,788,000 | -2.9% | 10,852 | +20.2% | 0.00% | – |
Q3 2021 | $162,522,000 | +458.9% | 9,029 | +445.2% | 0.00% | – |
Q2 2021 | $29,079,000 | +68.5% | 1,656 | -84.5% | 0.00% | – |
Q2 2020 | $17,261,000 | +56.1% | 10,655 | +0.2% | 0.00% | – |
Q1 2020 | $11,056,000 | -24.3% | 10,631 | +37.6% | 0.00% | – |
Q4 2019 | $14,600,000 | +144.9% | 7,725 | +40.0% | 0.00% | – |
Q3 2019 | $5,961,000 | -31.9% | 5,519 | +38.2% | 0.00% | – |
Q2 2019 | $8,747,000 | -80.3% | 3,994 | -46.1% | 0.00% | – |
Q1 2019 | $44,368,000 | +66120.9% | 7,407 | +82200.0% | 0.00% | – |
Q4 2018 | $67,000 | -99.5% | 9 | -98.9% | 0.00% | – |
Q3 2018 | $12,298,000 | -27.3% | 847 | 0.0% | 0.00% | – |
Q2 2018 | $16,915,000 | -80.5% | 847 | -82.9% | 0.00% | – |
Q1 2018 | $86,584,000 | -28.2% | 4,942 | +1.0% | 0.00% | – |
Q4 2017 | $120,661,000 | +135.2% | 4,893 | +146.1% | 0.00% | – |
Q3 2017 | $51,310,000 | -8.2% | 1,988 | -3.6% | 0.00% | – |
Q2 2017 | $55,921,000 | +7396.1% | 2,062 | +8148.0% | 0.00% | – |
Q1 2017 | $746,000 | -96.0% | 25 | -96.3% | 0.00% | – |
Q4 2016 | $18,455,000 | +3.4% | 680 | -2.4% | 0.00% | – |
Q3 2016 | $17,850,000 | +178.5% | 697 | +100.9% | 0.00% | – |
Q2 2016 | $6,409,000 | -77.1% | 347 | -66.6% | 0.00% | – |
Q4 2015 | $27,964,000 | – | 1,038 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 2,808,034 | $29,119,313 | 14.32% |
Foresite Capital Management V, LLC | 1,258,243 | $13,047,980 | 9.53% |
GREAT POINT PARTNERS LLC | 1,941,581 | $20,134,195 | 3.94% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $35,258,000 | 3.63% |
Aisling Capital Management LP | 434,455 | $4,505,298 | 2.21% |
SILVERARC CAPITAL MANAGEMENT, LLC | 651,400 | $6,755,018 | 2.09% |
VR Adviser, LLC | 1,040,754 | $10,792,619 | 1.73% |
Ikarian Capital, LLC | 796,300 | $8,257,631 | 1.32% |
Samsara BioCapital, LLC | 696,171 | $7,219,293 | 1.27% |
BRAIDWELL LP | 2,901,194 | $30,085,382 | 0.98% |